Investment in Affiliated Company	12 Months Ended
Dec. 31, 2012
Investment in Affiliated Company
Investment in Affiliated Company	(14) Investment in Affiliated Company In January 2010, the Company acquired a minority equity ownership interest in Luxcel Biosciences Limited (Luxcel) based in Cork, Ireland. The investment of €2.5 million (approximately $3.6 million) amounted to a 16.9% equity interest in Luxcel. The Company has evaluated the cost versus equity method of accounting for its investment in Luxcel and determined that it does not have the ability to exercise significant influence over the operating and financial policies of Luxcel and, therefore, accounts for its investment on a cost basis. The Company elected not to exercise the warrants to purchase an additional 375,000 shares of Luxcel's common stock by the January, 2013 deadline. This decision was based on management's evaluation of the cash needs throughout the entire Company. Luxcel has developed phosphorescence-based sensors that enable rapid, high-throughput screening and detection of bacterial contamination of food samples, non-invasive analysis of gas in food, beverage and pharmaceutical packaging, and one of the most specific measures of drug toxicity and metabolism within pharmaceutical research and development. The investment in Luxcel is carried on our consolidated balance sheet at the original purchase price, adjusted for currency fluctuations. The Company believes that it is not feasible to readily estimate the fair value of its investment in Luxcel. Information related to future cash flows of Luxcel is not readily available as the entity is a start-up research and development company and future cash flows are highly dependent on their ability to obtain additional funding, gain acceptance of its products in the marketplace, and obtain regulatory approvals. The Company performed its review of Luxcel at December 31, 2012 and determined that no triggering events had occurred which would indicate that there would be an other-than-temporary impairment of our investment. Luxcel has provided reimbursement for certain research and development costs incurred by the Company in the amounts of approximately $0, $175,000 and $165,000 in 2012, 2011 and 2010, respectively, which have been reflected in the Consolidated Statements of Income as a reduction of research and development expenses. As part of the relationship with Luxcel, we purchase sensors which accompany our instruments for sale to an end user and are required to pay a royalty to Luxcel on the sale of such instruments.

(14) Investment in Affiliated Company

In January 2010, the Company acquired a minority equity ownership interest in Luxcel Biosciences Limited (Luxcel) based in Cork, Ireland. The investment of €2.5 million (approximately $3.6 million) amounted to a 16.9% equity interest in Luxcel. The Company has evaluated the cost versus equity method of accounting for its investment in Luxcel and determined that it does not have the ability to exercise significant influence over the operating and financial policies of Luxcel and, therefore, accounts for its investment on a cost basis. The Company elected not to exercise the warrants to purchase an additional 375,000 shares of Luxcel's common stock by the January, 2013 deadline. This decision was based on management's evaluation of the cash needs throughout the entire Company.

Luxcel has developed phosphorescence-based sensors that enable rapid, high-throughput screening and detection of bacterial contamination of food samples, non-invasive analysis of gas in food, beverage and pharmaceutical packaging, and one of the most specific measures of drug toxicity and metabolism within pharmaceutical research and development.

The investment in Luxcel is carried on our consolidated balance sheet at the original purchase price, adjusted for currency fluctuations. The Company believes that it is not feasible to readily estimate the fair value of its investment in Luxcel. Information related to future cash flows of Luxcel is not readily available as the entity is a start-up research and development company and future cash flows are highly dependent on their ability to obtain additional funding, gain acceptance of its products in the marketplace, and obtain regulatory approvals. The Company performed its review of Luxcel at December 31, 2012 and determined that no triggering events had occurred which would indicate that there would be an other-than-temporary impairment of our investment. Luxcel has provided reimbursement for certain research and development costs incurred by the Company in the amounts of approximately $0, $175,000 and $165,000 in 2012, 2011 and 2010, respectively, which have been reflected in the Consolidated Statements of Income as a reduction of research and development expenses.

As part of the relationship with Luxcel, we purchase sensors which accompany our instruments for sale to an end user and are required to pay a royalty to Luxcel on the sale of such instruments.